LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$89.04 USD
-0.82 (-0.91%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $89.05 +0.01 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$89.04 USD
-0.82 (-0.91%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $89.05 +0.01 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
Zacks News
Here's Why You Should Add DaVita (DVA) to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
Reasons to Hold Baxter International (BAX) in Your Portfolio
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.
Why You Should Add Ensign Group (ENSG) to Your Portfolio Now
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on sustained top-line growth, a growing healthcare portfolio and solid operating cash flows.
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
BD's (BDX) Latest Product to Offer Wider Access to Researchers
by Zacks Equity Research
The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.
Here's Why Investors Should Hold Teladoc (TDOC) Stock Now
by Zacks Equity Research
Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.
Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock
by Zacks Equity Research
UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.
New Strong Buy Stocks for March 21st
by Zacks Equity Research
ANF, HENKY, PRLB, LMAT and GATX have been added to the Zacks Rank #1 (Strong Buy) List on March 21, 2023.
Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.
Best Momentum Stocks to Buy for March 13th
by Zacks Equity Research
ANF, LMAT and CRH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13, 2024.
New Strong Buy Stocks for March 13th
by Zacks Equity Research
SBSI, EBMT, LMAT, ANF and FHI have been added to the Zacks Rank #1 (Strong Buy) List on March 13, 2024.
Best Momentum Stocks to Buy for March 7th
by Zacks Equity Research
TOL, WILYY and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 7, 2023.
Ensign Group (ENSG) Buys Nursing Units, Boosts U.S. Footprint
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado and one similar facility in Kansas to better serve the regions' patients and grow its healthcare portfolio.
LeMaitre Vascular (LMAT) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does LeMaitre Vascular (LMAT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stocks to Buy for March 5th
by Zacks Equity Research
LMAT, SPXC and BBVA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 5, 2023.
LeMaitre (LMAT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MDT vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDT vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular (LMAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SurModics (SRDX) Reports Break-Even Earnings for Q1
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 100% and 3.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ESLOY or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
How Much Upside is Left in LeMaitre (LMAT)? Wall Street Analysts Think 25.24%
by Zacks Equity Research
The consensus price target hints at a 25.2% upside potential for LeMaitre (LMAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PETQ or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. LMAT: Which Stock Is the Better Value Option?
Prestige Consumer (PBH) Stock Rallies 20% in a Year: Here's Why
by Zacks Equity Research
Prestige Consumer (PBH) benefits from a robust healthcare brand portfolio and solid demand.
Here's Why Investors Should Retain Acadia Healthcare (ACHC)
by Zacks Equity Research
Acadia Healthcare (ACHC) is well-poised for growth on the solid demand for behavioral healthcare services, the continuous pursuit of expansion initiatives and growing cash reserves.
Encompass Health (EHC) Up 41% in a Year: More Room for Growth?
by Zacks Equity Research
Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.